Pharma BD Deal Intelligence
Johnson & Johnson (NYSE: JNJ) completed its acquisition of Halda Therapeutics OpCo, Inc. on December 29, 2025 for $3.05 billion in cash, having announced the definitive agreement on November 17, 2025. The deal brings J&J Halda's proprietary RIPTAC (Regulated Induced Proximity TArgeting Chimera) platform for oral, targeted solid-tumor therapies and its lead asset HLD-0915, a once-daily oral RIPTAC in a Phase 1/2 trial for metastatic castration-resistant prostate cancer (mCRPC). First-in-human data reported in October 2025 showed HLD-0915 was well tolerated with encouraging anti-tumor activity — among 22 patients completing ≥2 cycles, 59% achieved a PSA50 response and 32% a PSA90 response, alongside ctDNA reductions. J&J expects to accelerate the ongoing Phase 1/2 study (primary completion targeted March 2027) and extend RIPTAC into additional solid tumors.